FIELD: medicine.
SUBSTANCE: group of inventions refers to ophthalmology. A preventive and therapeutic agent is applied in posterior eye diseases. Pramipexole being a non-ergotamine selective D2 receptor antagonist, or its salt show inhibitory action on neovascularisation, suppressive action on photoreceptor cell damage and suppressive action on vascular hyperpermeability in posterior eye tissues, such as choroid or retina.
EFFECT: group of invention enables applying the agent as a preventive or therapeutic agent in posterior eye diseases, such as age-related macular degeneration, diabetic retinopathy or diabetic macular oedema.
14 cl, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF CABERGOLINE IN TREATING PATHOLOGICAL CONDITIONS CAUSED BY HIGH LEVELS OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR | 2016 |
|
RU2698728C1 |
| METHOD OF TREATING ATROPHIC AGE-RELATED MACULAR DEGENERATION | 2009 |
|
RU2521338C9 |
| METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION | 2009 |
|
RU2668371C2 |
| NEUTRAL ENDOPEPTIDASE (NEP) AND SOLUBLE HUMAN ENDOPEPTIDASE (SHE) INHIBITORS FOR PREVENTION AND TREATMENT OF EYE DISEASES | 2019 |
|
RU2758771C1 |
| TREATMENT OF EYE DISEASES SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH MEDICATIONS THAT ELIMINATE AGING CELLS | 2018 |
|
RU2815482C2 |
| INTRACHAMBER IMPLANTS WITH PROLONGED RELEASE OF THERAPEUTIC AGENT | 2011 |
|
RU2565445C2 |
| PEPTIDES FOR INHIBITING ANGIOGENESIS | 2016 |
|
RU2708375C2 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| LOCAL EYE PEPTIDE COMPOSITION | 2010 |
|
RU2561585C2 |
| METHOD OF TREATING OPHTHALMIC ANGIOGENESIS, RETINAL OEDEMA, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2445096C2 |
